Literature DB >> 81838

Immunoradiometric measurement of the factor VIII procoagulant antigen.

J Lazarchick, L W Hoyer.   

Abstract

A fluid-phase immunoradiometric assay has been developed which identifies an antigen on the Factor VIII (antihemophilic factor) procoagulant protein. This sensitive and quantitative assay is not influenced by levels of Favor VIII-related antigen (von Willebrand factor) or other plasma proteins. There is a close correlation of procoagulant activity and immunologically detectable protein in normal and von Willebrand's disease plasmas. In contrast, several different patterns have been identified in hemophilic plasmas. Neither procoagulant activity nor procoagulant antigen is detectable in plasmas from patients with severe classic hemophilia. Patients with mild and moderate hemophilia have either comparable plasma concentrations of procoagulant activity and procoagulant antigen or relatively greater levels of immunologically detectable protein.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 81838      PMCID: PMC371864          DOI: 10.1172/JCI109209

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

1.  Immunologic evidence that the antihemophilic factor (factor VIII)-like material in hemophilic plasma possesses a nonfunctional low molecular weight subcomponent.

Authors:  M C Poon; O D Ratnoff
Journal:  Blood       Date:  1977-09       Impact factor: 22.113

2.  The absorption of human factor VIII neutralizing antibody by factor VIII.

Authors:  R Biggs
Journal:  Br J Haematol       Date:  1974-02       Impact factor: 6.998

3.  Immunologic studies of antihemophilic factor (AHF, factor VIII): cross-reacting material in a genetic variant of hemophilia A.

Authors:  L W Hoyer; R T Breckenridge
Journal:  Blood       Date:  1968-12       Impact factor: 22.113

4.  Two types of haemophilia (A+ and A-): a study of 48 cases.

Authors:  K W Denson; R Biggs; M E Haddon; R Borrett; K Cobb
Journal:  Br J Haematol       Date:  1969-08       Impact factor: 6.998

5.  The isolation of IgG from mammalian sera with the aid of caprylic acid.

Authors:  M Steinbuch; R Audran
Journal:  Arch Biochem Biophys       Date:  1969-11       Impact factor: 4.013

6.  Enzymatic iodination of polypeptides with 125I to high specific activity.

Authors:  J I Thorell; B G Johansson
Journal:  Biochim Biophys Acta       Date:  1971-12-28

7.  Hemophilia A: polymorphism detectable by a factor 8 antibody.

Authors:  D Feinstein; M N Chong; C K Kasper; S I Rapaport
Journal:  Science       Date:  1969-03-07       Impact factor: 47.728

8.  Immunoradiometric assay of procoagulant factor-VIII antigen in plasma and serum and its reduction in haemophilia. Preliminary studies on adult and fetal blood.

Authors:  I R Peake; A L Bloom
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

9.  Interaction of factor VIII antigen in hemophilic plasmas with human antibodies to factor VIII.

Authors:  T S Zimmerman; L de la Pointe; T S Edgington
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.

Authors:  A R Thompson
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  16 in total

1.  Partial correction of a severe molecular defect in hemophilia A, because of errors during expression of the factor VIII gene.

Authors:  M Young; H Inaba; L W Hoyer; M Higuchi; H H Kazazian; S E Antonarakis
Journal:  Am J Hum Genet       Date:  1997-03       Impact factor: 11.025

2.  Hemophilia A due to mutations that create new N-glycosylation sites.

Authors:  A M Aly; M Higuchi; C K Kasper; H H Kazazian; S E Antonarakis; L W Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

4.  Moderately severe hemophilia A resulting from Glu----Gly substitution in exon 7 of the factor VIII gene.

Authors:  H Youssoufian; C Wong; S Aronis; H Platokoukis; H H Kazazian; S E Antonarakis
Journal:  Am J Hum Genet       Date:  1988-06       Impact factor: 11.025

5.  Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein.

Authors:  M Burton; H Nakai; P Colosi; J Cunningham; R Mitchell; L Couto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Two distinct forms of Factor VIII coagulant protein in human plasma. Cleavage by thrombin, and differences in coagulant activity and association with von Willebrand factor.

Authors:  M J Weinstein; L E Chute
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

7.  Combined functional and immunochemical analysis of normal and abnormal human factor X.

Authors:  D S Fair; E F Plow; T S Edgington
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

8.  Characterization of five partial deletions of the factor VIII gene.

Authors:  H Youssoufian; S E Antonarakis; S Aronis; G Tsiftis; D G Phillips; H H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

9.  Restriction endonuclease mapping of six novel deletions of the factor VIII gene in hemophilia A.

Authors:  H Youssoufian; C K Kasper; D G Phillips; H H Kazazian; S E Antonarakis
Journal:  Hum Genet       Date:  1988-10       Impact factor: 4.132

10.  Analysis of factor VIII coagulant antigen in normal, thrombin-treated, and hemophilic plasma.

Authors:  M Weinstein; L Chute; D Deykin
Journal:  Proc Natl Acad Sci U S A       Date:  1981-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.